| 000 | 01843 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250515160900.0 | ||
| 264 | 0 | _c20090326 | |
| 008 | 200903s 0 0 eng d | ||
| 022 | _a1091-6490 | ||
| 024 | 7 |
_a10.1073/pnas.0813333106 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSur, Surojit | |
| 245 | 0 | 0 |
_aA panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. _h[electronic resource] |
| 260 |
_bProceedings of the National Academy of Sciences of the United States of America _cMar 2009 |
||
| 300 |
_a3964-9 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAlleles |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xpharmacology |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 |
_aCyclin-Dependent Kinase Inhibitor p21 _xmetabolism |
| 650 | 0 | 4 |
_aG1 Phase _xdrug effects |
| 650 | 0 | 4 | _aGene Expression Profiling |
| 650 | 0 | 4 | _aGene Targeting |
| 650 | 0 | 4 | _aGenotype |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImidazoles _xmetabolism |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 |
_aNeoplasms _xpathology |
| 650 | 0 | 4 |
_aPiperazines _xmetabolism |
| 650 | 0 | 4 |
_aPteridines _xpharmacology |
| 650 | 0 | 4 |
_aTranscription, Genetic _xdrug effects |
| 650 | 0 | 4 |
_aTumor Suppressor Protein p53 _xgenetics |
| 650 | 0 | 4 | _aXenograft Model Antitumor Assays |
| 700 | 1 | _aPagliarini, Raymond | |
| 700 | 1 | _aBunz, Fred | |
| 700 | 1 | _aRago, Carlo | |
| 700 | 1 | _aDiaz, Luis A | |
| 700 | 1 | _aKinzler, Kenneth W | |
| 700 | 1 | _aVogelstein, Bert | |
| 700 | 1 | _aPapadopoulos, Nickolas | |
| 773 | 0 |
_tProceedings of the National Academy of Sciences of the United States of America _gvol. 106 _gno. 10 _gp. 3964-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1073/pnas.0813333106 _zAvailable from publisher's website |
| 999 |
_c18667851 _d18667851 |
||